Remed Co (302550.KQ) Stock Price

Remed Co Price

CLOSED
2,550.00
​
Market closed

Revenue has compounded at 18.6% per year over the past 8 years to 24.50 B KRW. Earnings per share have declined at 0.5% per year over the last 8 years. Remed Co's net margin stands at 2.1%, down from 3.7% several years earlier.

Remed Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Remed Co business model & stock analysis

REMED Co., Ltd. generates revenue through the manufacturing and sale of medical equipment, including transcranial magnetic stimulation (TMS) therapy machines, pain therapy machines, and biosignal and monitoring machines. Pain therapy machines encompass electromagnetic stimulation machines, extracorporeal shockwave therapy machines, and high intensity laser therapy machines. Biosignal and monitoring machines include patient monitors, fetal monitors, and electrocardiogram (ECG/EKG) machines. The company distributes these products domestically and internationally, targeting healthcare providers and medical facilities that require specialized therapeutic and monitoring solutions. The firm's product portfolio focuses on advanced medical devices for neurological and pain management, as well as patient monitoring. Transcranial magnetic stimulation (TMS) therapy machines are used for neurological treatments, while pain therapy machines address chronic pain conditions. Biosignal and monitoring machines support critical patient care, with electrocardiogram (ECG/EKG) machines being a key component. These products are sold to hospitals, clinics, and medical centers across domestic and overseas markets. REMED Co., Ltd. serves healthcare institutions that require specialized equipment for diagnosis, treatment, and monitoring. The domestic market includes hospitals and clinics in Daejeon, while overseas markets extend to international healthcare providers. The company’s revenue streams are derived from direct sales of its medical equipment, with no mention of additional services or licensing agreements in the business description.

Frequently asked questions about Remed Co

5 analysts currently rate the Remed Co stock: 4 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Remed Co share trades at 1.69 EUR (2,550.00 KRW).

The revenue cannot currently be calculated for Remed Co.

The profit cannot currently be calculated for Remed Co.

The P/E ratio cannot be calculated for Remed Co at the moment.

The P/S cannot be calculated for Remed Co currently.

The Eulerpool Quality Score for Remed Co is 2/10.

The ISIN of Remed Co is KR7302550009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Remed Co is 302550.KQ. The ticker symbol is used to trade Remed Co shares on the stock exchange.

Fair ValueTerminal
2,346.00 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website remed.kr
Country
South Korea
Currency
KRW
Initial public offering
Aug 14, 2018
ISIN
KR7302550009
Cusip
Y7S28A111
Market capitalization
85.42 B KRWLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
109.73
P/B Ratio
2.13
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
1.23 %
Last updated Nov 10, 2026, 3:45 AM

Remed Co Peer Group

Remed Co FIGI

302550:KS · BBG00LNLYGK6302550:KQ · BBG00LNLYGM4

All fundamentals and in-depth analysis of Remed Co

Our stock analysis for Remed Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Remed Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.